Pfizer Shrugs At Novartis’ Tekturna Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Oral renin inhibitors offer little to command a premium price over generic Norvasc, Pfizer R&D head says.
You may also be interested in...
Novartis’ Tekturna Is First Renin Inhibitor Approved For Hypertension
The first-in-class drug will launch later in March.
Pfizer Terminates Torcetrapib Program
Company will investigate whether an increased risk of mortality is a class effect of CETP inhibitors.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.